Atrial fibrosis and the mechanisms of atrial fibrillation

Thomas Everett, Jeffrey E. Olgin

Research output: Contribution to journalArticle

207 Citations (Scopus)

Abstract

Atrial fibrillation (AF) is commonly associated with congestive heart failure (CHF), and CHF has been shown to be associated with atrial structural remodeling resulting in fibrosis. Atrial interstitial fibrosis has been seen in patients with CHF and in animal models of pacing-induced heart failure. With atrial fibrosis, conduction abnormalities result in increased AF vulnerability. The mechanism of AF associated with CHF is under debate, as both focal and reentrant mechanisms have been observed in animal models of CHF. However, recent studies using frequency-domain analysis have shown that the AF within this model is characterized by discrete, stable, high-frequency areas. The precise signaling processes involved in the development of atrial fibrosis are unknown. Angiotensin appears to play a role, as inhibition of angiotensin-converting enzyme (or angiotensin-receptor blocker) blunts atrial fibrosis in animal models of heart failure and decreases the incidence of AF in patients with heart failure. Transforming growth factor-β (TGF-β) also appears to play an important role. Mouse models that overexpress TGF-β1 have profound atrial fibrosis and AF (with normal ventricles). Heart failure in canine models also produces increases in atrial TGF-β1 expression, and inhibition of this expression prevents atrial fibrosis and the development of a substrate for AF. Atrial fibrosis appears to play a role in the development of a vulnerable substrate for AF, especially in the setting of CHF.

Original languageEnglish (US)
JournalHeart Rhythm
Volume4
Issue number3 SUPPL.
DOIs
StatePublished - Mar 2007
Externally publishedYes

Fingerprint

Atrial Fibrillation
Fibrosis
Heart Failure
Transforming Growth Factors
Animal Models
Atrial Remodeling
Angiotensin Receptor Antagonists
Angiotensins
Peptidyl-Dipeptidase A
Canidae
Incidence

Keywords

  • Atrial fibrillation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Atrial fibrosis and the mechanisms of atrial fibrillation. / Everett, Thomas; Olgin, Jeffrey E.

In: Heart Rhythm, Vol. 4, No. 3 SUPPL., 03.2007.

Research output: Contribution to journalArticle

Everett, Thomas ; Olgin, Jeffrey E. / Atrial fibrosis and the mechanisms of atrial fibrillation. In: Heart Rhythm. 2007 ; Vol. 4, No. 3 SUPPL.
@article{cf678fd1dfdb4d30a790185385be384d,
title = "Atrial fibrosis and the mechanisms of atrial fibrillation",
abstract = "Atrial fibrillation (AF) is commonly associated with congestive heart failure (CHF), and CHF has been shown to be associated with atrial structural remodeling resulting in fibrosis. Atrial interstitial fibrosis has been seen in patients with CHF and in animal models of pacing-induced heart failure. With atrial fibrosis, conduction abnormalities result in increased AF vulnerability. The mechanism of AF associated with CHF is under debate, as both focal and reentrant mechanisms have been observed in animal models of CHF. However, recent studies using frequency-domain analysis have shown that the AF within this model is characterized by discrete, stable, high-frequency areas. The precise signaling processes involved in the development of atrial fibrosis are unknown. Angiotensin appears to play a role, as inhibition of angiotensin-converting enzyme (or angiotensin-receptor blocker) blunts atrial fibrosis in animal models of heart failure and decreases the incidence of AF in patients with heart failure. Transforming growth factor-β (TGF-β) also appears to play an important role. Mouse models that overexpress TGF-β1 have profound atrial fibrosis and AF (with normal ventricles). Heart failure in canine models also produces increases in atrial TGF-β1 expression, and inhibition of this expression prevents atrial fibrosis and the development of a substrate for AF. Atrial fibrosis appears to play a role in the development of a vulnerable substrate for AF, especially in the setting of CHF.",
keywords = "Atrial fibrillation",
author = "Thomas Everett and Olgin, {Jeffrey E.}",
year = "2007",
month = "3",
doi = "10.1016/j.hrthm.2006.12.040",
language = "English (US)",
volume = "4",
journal = "Heart Rhythm",
issn = "1547-5271",
publisher = "Elsevier",
number = "3 SUPPL.",

}

TY - JOUR

T1 - Atrial fibrosis and the mechanisms of atrial fibrillation

AU - Everett, Thomas

AU - Olgin, Jeffrey E.

PY - 2007/3

Y1 - 2007/3

N2 - Atrial fibrillation (AF) is commonly associated with congestive heart failure (CHF), and CHF has been shown to be associated with atrial structural remodeling resulting in fibrosis. Atrial interstitial fibrosis has been seen in patients with CHF and in animal models of pacing-induced heart failure. With atrial fibrosis, conduction abnormalities result in increased AF vulnerability. The mechanism of AF associated with CHF is under debate, as both focal and reentrant mechanisms have been observed in animal models of CHF. However, recent studies using frequency-domain analysis have shown that the AF within this model is characterized by discrete, stable, high-frequency areas. The precise signaling processes involved in the development of atrial fibrosis are unknown. Angiotensin appears to play a role, as inhibition of angiotensin-converting enzyme (or angiotensin-receptor blocker) blunts atrial fibrosis in animal models of heart failure and decreases the incidence of AF in patients with heart failure. Transforming growth factor-β (TGF-β) also appears to play an important role. Mouse models that overexpress TGF-β1 have profound atrial fibrosis and AF (with normal ventricles). Heart failure in canine models also produces increases in atrial TGF-β1 expression, and inhibition of this expression prevents atrial fibrosis and the development of a substrate for AF. Atrial fibrosis appears to play a role in the development of a vulnerable substrate for AF, especially in the setting of CHF.

AB - Atrial fibrillation (AF) is commonly associated with congestive heart failure (CHF), and CHF has been shown to be associated with atrial structural remodeling resulting in fibrosis. Atrial interstitial fibrosis has been seen in patients with CHF and in animal models of pacing-induced heart failure. With atrial fibrosis, conduction abnormalities result in increased AF vulnerability. The mechanism of AF associated with CHF is under debate, as both focal and reentrant mechanisms have been observed in animal models of CHF. However, recent studies using frequency-domain analysis have shown that the AF within this model is characterized by discrete, stable, high-frequency areas. The precise signaling processes involved in the development of atrial fibrosis are unknown. Angiotensin appears to play a role, as inhibition of angiotensin-converting enzyme (or angiotensin-receptor blocker) blunts atrial fibrosis in animal models of heart failure and decreases the incidence of AF in patients with heart failure. Transforming growth factor-β (TGF-β) also appears to play an important role. Mouse models that overexpress TGF-β1 have profound atrial fibrosis and AF (with normal ventricles). Heart failure in canine models also produces increases in atrial TGF-β1 expression, and inhibition of this expression prevents atrial fibrosis and the development of a substrate for AF. Atrial fibrosis appears to play a role in the development of a vulnerable substrate for AF, especially in the setting of CHF.

KW - Atrial fibrillation

UR - http://www.scopus.com/inward/record.url?scp=33847252976&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847252976&partnerID=8YFLogxK

U2 - 10.1016/j.hrthm.2006.12.040

DO - 10.1016/j.hrthm.2006.12.040

M3 - Article

C2 - 17336879

AN - SCOPUS:33847252976

VL - 4

JO - Heart Rhythm

JF - Heart Rhythm

SN - 1547-5271

IS - 3 SUPPL.

ER -